| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T37 |
0-333 |
Sentence |
denotes |
Although developed targeting the oncogenic fusion protein BCR-ABL, imatinib is able to inhibit other tyrosine kinases such as c-KIT, platelet-derived growth factor receptor and Abelson kinases (ABL) type 1 and 2 [4]; therefore, it has been postulated that the biological activity of this drug is not restricted to anticancer effects. |
| T38 |
334-409 |
Sentence |
denotes |
In this regard, immunomodulatory properties of imatinib have been reported. |
| T39 |
410-736 |
Sentence |
denotes |
Murine models of sepsis and acute lung injury have suggested a protective role of this drug by reducing pulmonary edema, preventing histological damage and improving endothelial barrier dysfunction, probably through attenuation of proinflammatory cytokine release including interleukin-6 and tumor necrosis factor-alpha [4,5]. |
| T40 |
737-946 |
Sentence |
denotes |
These effects over inflammatory activation might be mediated by the inhibition of transcription factor NF-κB according to previous evidence from both animal models and studies with human cells [[4], [5], [6]]. |
| T41 |
947-1100 |
Sentence |
denotes |
Since NF-κB represents a key element in several inflammatory pathways [7], imatinib could be helpful to modulate host immune response against SARS-CoV-2. |
| T42 |
1101-1208 |
Sentence |
denotes |
This is particularly noteworthy given that hyperinflammation plays a central role in severe COVID-19 [3,8]. |
